Figure S1. TNFRSF9 expression in primary non-diffuse tumours and malformations. Haematoxylin and eosin (HE) stainings (left AD) and immunohistochemistry for TNFRSF9 (middle AD and CD right) as well as for BRAF V600E (right A) and phosphoS6 (right B) in (A) a pleomorphic xanthoastrocytoma (PXA), (B) subependymal giant cell astrocytoma (SEGA), (C) focal cortical dysplasia (FCD) and (D) ganglioglioma. (Scale bars: 200 μm in AB; 100 μm in CD left and middle; 50 μm in CD right.)


Figure S2. TNFRSF9 expression is associated with reactive astrogliosis also in non-neoplastic CNS lesions. HE stainings (left AE) and immunohistochemistry for TNFRSF9 (middle AE) of (A) ischemic stroke (tissue surrounding a pseudocyst of an old infarction > 6 months), (B) cavernoma, (C) an acute demyelinating encephalomyelitis (ADEM), (D) CNS tissue surrounding a CNS lymphoma and (E) foetal CNS tissue suffering from intrauterine hypoxia (subventricular zone) are depicted. (Scale bars: 50 μm in A right, C left and right, D right, E middle and right; 100 μm in A left and middle, B right, C middle, D left and middle and E left; 200 μm in B left and middle.)


Table S1. Patient data of neoplastic and non-neoplastic CNS lesions.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.